CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Ivermectin 5 MG/MLWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2784 conjunctival RT PCR Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19

The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.

NCT04425863 Severe Acute Respiratory Syndrome Ventilation Pneumonitis Drug: Ivermectin 5 MG/ML
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Pneumonia

Primary Outcomes

Description: Considering healing and/or reducing symptoms and severity of initial presentation

Measure: Illness development

Time: 7 days

Description: Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive care

Measure: Reduction of need ICU admission

Time: 14 days

Description: Preventing patient from dying

Measure: Reduction of mortality rate

Time: 30 days

Secondary Outcomes

Description: potential need of reducing or augmenting doses

Measure: Optimyzing doses of drugs used in the clinical trial

Time: 14 days

Description: Outcome of adverse effects to one or more drugs used in the clinical trial

Measure: Adverse effects

Time: 14 days

Related HPO nodes (Using clinical trials)